Crohn’s Disease – Current Treatment – Current Treatment: Physician Insights – Crohn’s Disease (EU5)
Multiple well-established therapies are available to treat Crohn’s disease (CD). The mostly widely used biologics, the TNF-α inhibitors (e.g., Janssen / Merck’s Remicade, AbbVie / Eisai’s Humira), are entrenched as first-line biologics, and non-TNF inhibitors (e.g., Takeda’s Entyvio, Janssen’s Stelara) have helped advance CD treatment, especially for moderate to severe disease. In the past three years, two novel therapies have launched for CD (i.e., AbbVie’s Skyrizi and Rinvoq). The launch of subcutaneous forms of Entyvio and infliximab is further expanding physicians’ treatment armamentarium. The availability of these agents will continue to impact the treatment landscape.
Questions answered:
- Which drug classes are the patient-share leaders in each line of therapy? How are various biological agents being positioned in surveyed physicians’ treatment algorithm?
- What are the most influential drivers of treatment selection, and under which scenarios do/will physicians prescribe Skyrizi and Rinvoq?
- What are the common treatment scenarios before initiating the various biological agents (i.e., Remicade, Humira, biosimilar infliximab, biosimilar adalimumab, Entyvio, Stelara, Skyrizi, and Rinvoq)? What is the course of action upon discontinuing these agents?
- What factors drive therapy discontinuation and switch? What factors have driven/will drive recent/anticipated prescribing changes?
Markets covered: France, Germany, Italy, Spain, and the United Kingdom
Primary research: 250 gastroenterologists completed the survey. Of these physicians, 50 were in France, 50 in Germany, 50 in Italy, 50 in Spain, and 50 in the United Kingdom. The survey was fielded in March 2024.
Key companies: Merck & Co., Celltrion, Hospira, Biogen, AbbVie / Eisai, Biogen, Amgen, Sandoz, Takeda, Johnson & Johnson Innovative Medicine
Key drugs: Remicade, Humira, Entyvio, Stelara, Skyrizi, Rinvoq, biosimilars
Product description: Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
.
